Abstract
Multiple sclerosis (MS) is a disease of demyelinating nature affecting the central nervous system. The chronic inflammation gives rise to plaques in the white and grey matter of the spinal cord and brain regions and also leads to diffuse neurodegeneration in the majority of the brain. Molecular biomarkers for MS are derived from the branches of neurobiology and immunology owing to the causal pathomechanisms. Currently, there is no definite cure for MS and its treatment is mainly centered on the administration of immunosuppressive and immunomodulating agents. Existing management approaches are dedicated to the reduction of biological activity through DMTs, treating acute attacks, and symptomatic treatment. Experimental models are essential to evolving the complexity and pathogenetic mechanisms of the disease and in the design of specific and effective treatments. Various in vitro and in vivo models have been developed in the quest for the design of experimental models of MS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Medical Pharmaceutical And Allied Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
